Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 18,391 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Active, not recruiting Phase 1 Interventional

Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

NCT05223829
View directory record Official record
Conditions
PTSD, Alcohol Use Disorder
Interventions
Brexanolone
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 20, 2026, 8:51 PM EDT
Not listed Not applicable Interventional

Fetal Growth Restriction: Management Using Two Guidelines - Fetal Growth Antenatal Management Evaluation

NCT05938829
View directory record Official record
Conditions
Fetal Growth Retardation
Interventions
Ultrasound following the SMFM guidelines, Ultrasound following the ISUOG guidelines
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Not listed
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

NCT02192931
View directory record Official record
Conditions
Depression, Dual Diagnosis, Drug Addiction
Interventions
Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 20, 2026, 8:51 PM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of [225Ac]-FPI-1434 Injection

NCT03746431
View directory record Official record
Conditions
Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Interventions
[111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion, [225Ac]-FPI-1434 Injection single-dose
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Not applicable Interventional

Preventing Obesity in Military Communities, Adolescents

NCT02334202
View directory record Official record
Conditions
Obesity, Weight Gain, Disordered Eating, Eating Disorder
Interventions
Interpersonal Psychotherapy-Weight Gain, Health Education
Behavioral · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
12 Years to 17 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Not applicable Interventional Results available

Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action

NCT01439854
View directory record Official record
Conditions
Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 20, 2026, 8:51 PM EDT
Active, not recruiting Not applicable Interventional

Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy

NCT04586166
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions
RP Sling, SIS
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
5
States / cities
Coconut Creek, Florida • Augusta, Georgia • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy

NCT06397456
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
In-Person Patient Education, Commitment to Change, Blood pressure monitoring, Written Patient Education, Text-based reinforcement for CKD self-management, Community-based education session, reinforcement for self-management, Text-based reinforcement for general health self-management
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 20, 2026, 8:51 PM EDT
Recruiting Not applicable Interventional

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT05287451
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer
Interventions
RIsk-Reducing Salpingectomy (RRS), Risk-Reducing Oophorectomy-RRO, Risk-Reducing Salpingo-Oophorectomy-RRSO
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Recruiting Phase 4 Interventional

A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

NCT07654751
View directory record Official record
Conditions
Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
Interventions
Breast Milk Sample Collection, Guselkumab
Procedure · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Completed No phase listed Observational

Environmental Factors in the Development of Polycystic Ovary Syndrome

NCT00341731
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Research Triangle Park, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 3 Interventional Results available

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy

NCT00233402
View directory record Official record
Conditions
Bladder Cancer
Interventions
Hexvix, Standard white light cystoscopy
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 20, 2026, 8:51 PM EDT
Completed No phase listed Observational

Examining Heart Attacks in Young Women

NCT00597922
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
2,985 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
92
States / cities
Birmingham, Alabama • Mobile, Alabama • La Mesa, California + 76 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 20, 2026, 8:51 PM EDT
Terminated Phase 1 Interventional

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00014131
View directory record Official record
Conditions
Kidney Cancer
Interventions
Biological/Vaccine: therapeutic autologous dendritic cells.
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 20, 2026, 8:51 PM EDT
Recruiting Phase 4 Interventional

Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study

NCT04207931
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Topical steroid class I-II, Triamcinolone Acetonide, Doxycyline, Minoxidil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Enrolling by invitation No phase listed Observational

Recovery and Symptom Relief Following Percutaneous Ablation of Abdominal Wall Endometriosis

NCT06268951
View directory record Official record
Conditions
Endometriosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

NCT00768729
View directory record Official record
Conditions
Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression
Interventions
Sirolimus, MMF or Azathioprine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Madera, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 20, 2026, 8:51 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102, TURBT
Drug · Procedure
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants

NCT02632266
View directory record Official record
Conditions
Complication of Prematurity
Interventions
Powder HMF, Liquid HMF
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
28 Weeks to 34 Weeks
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 4 Interventional Results available

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

NCT04790279
View directory record Official record
Conditions
Hypertension in Pregnancy
Interventions
Amlodipine, NIFEdipine ER
Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 3 Interventional

The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence

NCT00492596
View directory record Official record
Conditions
Urinary Incontinence, Stress
Interventions
AttenueX IntraVesical System, Sham Procedure
Device · Procedure
Lead sponsor
Solace Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
13
States / cities
Tucson, Arizona • Downey, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 20, 2026, 8:51 PM EDT
Withdrawn Not applicable Interventional

Dino Egg in Neonatal Intensive Care Unit

NCT03447405
View directory record Official record
Conditions
Premature Birth
Interventions
Dino Egg
Device
Lead sponsor
Jonathan Slaughter
Other
Eligibility
32 Weeks to 34 Weeks
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 20, 2026, 8:51 PM EDT
Completed Phase 1 Interventional

Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer

NCT01652794
View directory record Official record
Conditions
Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pseudomyxoma Peritonei, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
stereotactic body radiation therapy, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacogenomic studies
Radiation · Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 20, 2026, 8:51 PM EDT